BioLineRx Ltd.
A clinical-stage biopharmaceutical company developing therapies for oncology and rare diseases.
BLRX | TA
Overview
Corporate Details
- ISIN(s):
- US09071M2052 (+1 more)
- LEI:
- 529900AKIOSC15Y63R18
- Country:
- Israel
- Address:
- Modi'in Technology Park, 2 HaMa'ayan Street, 7177871 Modi'in
- Website:
- https://www.biolinerx.com/
- Sector:
- Manufacturing
Description
BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for oncology and rare diseases. The company leverages its drug development capabilities to advance novel, early-stage therapeutic candidates through the clinical development process toward regulatory approval. Its pipeline consists of treatments, including small molecules, designed to address unmet medical needs and deliver meaningful benefits to patients. BioLineRx also partners with other drug developers to advance their early-stage programs.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-01-20 01:40 |
Announces $10 Million Bought Deal Offering
|
English | 14.6 KB | ||
| 2021-01-20 01:40 |
Announces $10 Million Bought Deal Offering
|
English | 35.9 KB | ||
| 2021-01-02 22:09 |
PROSPECTUS SUPPLEMENT Dated December 31, 2020
|
English | 302.8 KB | ||
| 2021-01-02 22:09 |
PROSPECTUS SUPPLEMENT Dated December 31, 2020
|
English | 35.9 KB | ||
| 2021-01-02 22:08 |
Shelf Registration Statement
|
English | 697.5 KB | ||
| 2021-01-02 22:08 |
Shelf Registration Statement
|
English | 35.9 KB | ||
| 2020-12-16 15:59 |
Presentation for KOL webinar to discuss final results from COMBAT / KEYNOTE-202…
|
English | 6.0 MB | ||
| 2020-12-16 15:59 |
Presentation for KOL webinar to discuss final results from COMBAT / KEYNOTE-202…
|
English | 36.0 KB | ||
| 2020-12-16 13:59 |
Final Results from Phase 2a COMBAT/KEYNOTE-202 Triple Combination Study of Moti…
|
English | 76.3 KB | ||
| 2020-12-16 13:59 |
Final Results from Phase 2a COMBAT/KEYNOTE-202 Triple Combination Study of Moti…
|
English | 36.1 KB | ||
| 2020-11-23 14:59 |
Third Quarter 2020 Financial Results
|
English | 410.0 KB | ||
| 2020-11-23 14:59 |
Third Quarter 2020 Financial Results
|
English | 36.2 KB | ||
| 2020-11-18 14:59 |
Initiation of Phase 1b Clinical Trial in Patients with Acute Respiratory Distre…
|
English | 79.1 KB | ||
| 2020-11-18 14:59 |
Initiation of Phase 1b Clinical Trial in Patients with Acute Respiratory Distre…
|
English | 36.1 KB | ||
| 2020-11-15 09:33 |
PROSPECTUS SUPPLEMENT-Up to $4,430,000 of American Depositary Shares Representi…
|
English | 239.5 KB |
Automate Your Workflow. Get a real-time feed of all BioLineRx Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BioLineRx Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BioLineRx Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
